Bladder Cancer
Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody.
April 7, 2024
The Paris System for reporting urinary cytology improves the negative predictive value of high-grade urothelial carcinoma.
April 6, 2024
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.
April 5, 2024
Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer.
April 5, 2024
Head-to-head Intra-individual Comparison of [68Ga]-FAPI and [18F]-FDG PET/CT in Patients with Bladder Cancer.
April 5, 2024
Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer.
April 5, 2024
Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer.
April 4, 2024
NPEPPS Is a Druggable Driver of Platinum Resistance.
April 4, 2024
Antibody-Drug Conjugate Combination Therapy in Patients with Metastatic Urothelial Cancer - Expert Commentary
April 3, 2024
Mechanism of action of nadofaragene firadenovec-vncg.
April 3, 2024